Bicocca Open Archive

Logo unimib boa
POGLIANI, ENRICO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.541
EU - Europa 4.522
AS - Asia 4.302
SA - Sud America 796
AF - Africa 88
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 9
Totale 20.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.285
SG - Singapore 1.438
CN - Cina 1.271
HK - Hong Kong 866
DE - Germania 788
RU - Federazione Russa 742
BR - Brasile 646
SE - Svezia 638
IE - Irlanda 612
UA - Ucraina 549
IT - Italia 489
VN - Vietnam 269
GB - Regno Unito 237
CA - Canada 204
FI - Finlandia 136
IN - India 114
KR - Corea 99
FR - Francia 81
AR - Argentina 55
JP - Giappone 46
NL - Olanda 46
ZA - Sudafrica 42
AT - Austria 39
BD - Bangladesh 39
EC - Ecuador 39
DK - Danimarca 34
MX - Messico 34
TR - Turchia 34
BE - Belgio 28
IQ - Iraq 27
PL - Polonia 27
ES - Italia 24
ID - Indonesia 21
EU - Europa 14
CO - Colombia 12
MA - Marocco 12
PY - Paraguay 12
PK - Pakistan 11
SA - Arabia Saudita 11
LT - Lituania 10
CL - Cile 9
EG - Egitto 9
VE - Venezuela 9
BG - Bulgaria 8
UY - Uruguay 8
AU - Australia 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
KE - Kenya 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
TN - Tunisia 5
IL - Israele 4
IR - Iran 4
MY - Malesia 4
NP - Nepal 4
PT - Portogallo 4
ET - Etiopia 3
HU - Ungheria 3
JO - Giordania 3
MK - Macedonia 3
PA - Panama 3
PE - Perù 3
TH - Thailandia 3
AL - Albania 2
BH - Bahrain 2
BO - Bolivia 2
BW - Botswana 2
BY - Bielorussia 2
DZ - Algeria 2
HR - Croazia 2
JM - Giamaica 2
OM - Oman 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
CH - Svizzera 1
CR - Costa Rica 1
CU - Cuba 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MU - Mauritius 1
MZ - Mozambico 1
NI - Nicaragua 1
Totale 20.266
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.839
Woodbridge 1.038
Hong Kong 866
Ashburn 838
Singapore 771
Houston 748
Fairfield 647
Dublin 599
Jacksonville 588
Chandler 457
Frankfurt am Main 390
Wilmington 373
Dearborn 323
New York 284
Seattle 258
Princeton 224
Cambridge 207
Beijing 196
Milan 150
Los Angeles 146
Hefei 142
Santa Clara 134
Nanjing 129
Shanghai 119
Lawrence 103
Lachine 102
Altamura 100
Seoul 96
Ho Chi Minh City 87
Dallas 86
Moscow 77
Buffalo 72
Chicago 66
Hanoi 62
São Paulo 60
The Dalles 57
Göttingen 52
Guangzhou 44
Nanchang 42
Changsha 40
Andover 37
Toronto 35
San Diego 34
Shenyang 32
Vienna 32
Ottawa 29
Brussels 28
Hebei 28
London 27
Munich 27
Tokyo 27
Boardman 23
Warsaw 23
Huizen 22
Rio de Janeiro 22
Helsinki 21
Johannesburg 20
Salt Lake City 19
Atlanta 18
Fürstenwalde 18
Jiaxing 18
Jinan 18
Tampa 18
Tianjin 18
Fremont 17
Montreal 17
Denver 16
Hangzhou 16
Lissone 16
Norwalk 16
Redmond 16
Chennai 15
Council Bluffs 15
Nürnberg 15
Pune 15
University Park 15
Zhengzhou 15
Brooklyn 13
Haiphong 13
Kunming 13
Mountain View 13
Boston 12
Guayaquil 12
New Delhi 12
Orem 12
Poplar 12
Turku 12
Campinas 11
Elk Grove Village 11
Rome 11
Stockholm 11
Brasília 10
Manchester 10
Porto Alegre 10
Quito 10
San Francisco 10
Curitiba 9
Dhaka 9
Falls Church 9
Mexico City 9
Totale 13.664
Salva come PNG Salva come JPEG
Nome #
Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease 489
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia 420
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 419
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 380
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 376
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 345
Imatinib long term effects study: three years of follow-up and assessment 333
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 331
A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation 327
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 312
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 305
Thrombosis of the splenoportal axis after splenectomy 264
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 254
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 248
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 247
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 246
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 245
Severe, reversible nelarabine-induced neuropathy and myelopathy 244
Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report 242
A prospective study on cardiovascular events after acute pulmonary embolism 233
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 233
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 233
Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma 217
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) 217
Combined prophylactic low-molecular weight heparin and low dose aspirin reduces the occurrences of adverse pregnancy outcome in multiparous women with preeclampsia and intrauterine fetal growth restriction in antecedent pregnancy 214
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 213
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease 213
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 212
Recurrent preeclapsia: The role of acquired and heritable thrombophilia 211
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 211
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination 204
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies 202
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 202
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone 201
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report 200
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 200
Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy 199
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 197
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 195
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 195
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 195
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 194
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study 192
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance 184
Platelet activation during plasma-reduced multicomponent PLT collection: A comparison between COBE Trima and Spectra LRS turbo cell separators 183
Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? 181
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease 180
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 178
Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy 178
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group 177
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 176
Crizotinib in anaplastic large-cell lymphoma 176
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 176
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study 173
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 173
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 172
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 168
Frozen-and-thawed allogeneic platelet gels for treating postoperative chronic wounds 167
Reviewed diagnosis of primary and secondary immune thrombocytopenic purpura in 79 adult patients hospitalized in 2000 - 2002 165
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies 164
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) 164
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 162
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 161
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 160
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 158
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials 158
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00 157
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system 155
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 153
A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript 151
HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY 151
Development of c-Kit-expressing Small-Cell lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment 150
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia 150
Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program 145
SIGNIFICANT REDUCTION IN FASTING BLOOD GLUCOSE IN NONDIABETIC PH+ CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE 143
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 140
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 140
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 139
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared? 139
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature 138
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 138
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD 135
Advanced mast cell disease: an Italian Hematological Multicenter experience 134
Atypical presentation of Upshaw-Schulman syndrome in a pregnant patient homozygous for V Leiden mutation 130
Imatinib concentrations in human milk 129
Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions 129
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 128
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 127
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 125
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 122
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate 121
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 121
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome 119
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 119
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments 118
Low Efficiency of a Newly Introduced High-Density Microparticles Method for B Cell Depletion in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation 118
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [2] 117
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients 116
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study 114
Mast cell leukemia: A report of ten cases 114
Totale 19.469
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.472
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.472
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021883 0 0 0 0 0 108 168 100 176 180 66 85
2021/20221.088 50 58 90 111 85 103 42 85 71 92 106 195
2022/20232.038 293 671 195 163 127 311 17 79 109 6 34 33
2023/20241.665 38 45 54 78 244 490 341 47 174 13 21 120
2024/20253.085 211 356 120 138 296 75 122 75 319 462 312 599
2025/20264.058 764 566 669 953 969 137 0 0 0 0 0 0
Totale 20.596